Anti-Hair-Loss Shampoo and Japan's Quasi-Drug Rule: The Classification Mistake That Stops Customs Clearance

Regulatory Classification · Japan · Anti-Hair-Loss Shampoo

Per Japan's Pharmaceutical and Medical Device Act, an anti-hair-loss claim reclassifies the shampoo as a quasi-drug, not a cosmetic — requiring a licensed Marketing Authorization Holder and an accredited overseas factory before a single unit clears customs.

· July 2026 · 7 min read

An anti-hair-loss claim is what turns a Japan-bound shampoo shipment into a licensing problem: Japan's Pharmaceutical and Medical Device Act treats hair-growth products as a quasi-drug (医薬部外品), not a cosmetic, so the importer needs a licensed Marketing Authorization Holder and an accredited overseas factory in place before a single unit clears customs — requirements a plain cosmetic never triggers. This guide covers the classification rule, the licenses exporters miss, and a realistic approval timeline.

The Mistake: Treating a Hair-Growth Claim Like an Ordinary Cosmetic Claim

Many anti-hair-loss shampoos are sold and registered as ordinary cosmetics in their home market. It is natural to assume that shipping the same product to Japan just means translating the label and finding a distributor. That assumption is the single mistake behind most stalled shipments in this product category.

Japan Customs explicitly names hair-growth agents as an example of the quasi-drug (医薬部外品) product category, a category kept legally separate from cosmetics under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices — Japan's PMD Act. The claim on the bottle, not the product's category back home, decides which path Japan applies.

Quasi-Drug (Anti-Hair-Loss Claim) vs. Cosmetic (No Efficacy Claim)

	Quasi-Drug (Anti-Hair-Loss Claim)	Cosmetic (No Efficacy Claim)
Marketing authorization	Japan-based Marketing Authorization Holder must hold a Quasi-Drug Manufacturing and Sales Business Permit (医薬部外品製造販売業許可)	Holder of a Cosmetic Manufacturing and Sales Business Permit (化粧品製造販売業許可), notification-based (Saitama Prefecture)
Pre-market approval	Product-specific marketing approval required, roughly 6 to 12 months depending on the source	No pre-market approval -- notification only (REACH24H Consulting Group)
Efficacy claim (e.g., hair growth / anti-hair-loss)	Permitted, if formulated with an MHLW-approved active ingredient at the mandated concentration (JPRO)	Not legally permitted -- even a softer phrase like a 'hair-growth environment' has been rejected (Yakujihou.com)
Customs clearance document	Manufacturing and Sales Business License or Import Confirmation Certificate must be shown at clearance (Japan Customs)	Standard cosmetics import documentation; not subject to this quasi-drug requirement

Why the Claim Triggers Japan's Quasi-Drug Classification

Quasi-drugs in Japan are defined by ingredient and purpose, not by marketing intent. A Japan-focused life-science regulatory portal, JPRO, describes quasi-drugs as products containing an active ingredient the Ministry of Health, Labour and Welfare (MHLW) has approved, at a specified concentration, for a specific declared purpose such as hair growth, whitening, or acne prevention. A product cannot legally carry a hair-loss-prevention claim unless it uses one of those approved ingredients at the required strength.

Hair-growth and anti-hair-loss products sit alongside deodorants, hair dyes, and medicated whitening or acne products on Japan's quasi-drug list, according to regulatory consultancy REACH24H. The gap between the two tracks is not small: a 2013 newsletter from Japanese pharmaceutical-law consultancy Yakujihou.com shows a real example where regulators rejected even the softer phrase "hair-growth environment" on an ordinary cosmetic, because only a quasi-drug-classified product may make that kind of claim at all.

Which Path Does Your Shampoo Fall Into?

Does the product make a hair-growth or anti-hair-loss efficacy claim?

• No efficacy claim (plain cosmetic)→ File as an ordinary cosmetic notification -- no pre-market approval required (REACH24H Consulting Group)
• Claim made, formulated with an MHLW-approved active ingredient at the mandated concentration→ Classified as a quasi-drug -- requires a Japan-based Marketing Authorization Holder, Accreditation of the Foreign Manufacturer for the overseas factory, and product-specific marketing approval before commercial customs clearance
• Claim made, but the active ingredient is not on MHLW's approved list→ The claim cannot legally be made in Japan -- drop the anti-hair-loss claim and file as an ordinary cosmetic instead (JPRO; Yakujihou.com)

Three Requirements First-Time Exporters Miss

Once the product is confirmed as a quasi-drug, three separate requirements apply that a cosmetics shipment never has to deal with.

First, a Japan-based Marketing Authorization Holder must be in place. Saitama Prefecture's Pharmaceutical Affairs Division confirms that this entity needs its own Quasi-Drug Manufacturing and Sales Business Permit (医薬部外品製造販売業許可) — a distinct license from the Cosmetic Manufacturing and Sales Business Permit used for ordinary cosmetics.

Second, the overseas factory needs its own clearance. PMDA's official application documentation states that a quasi-drug manufactured outside Japan must first obtain Accreditation of the Foreign Manufacturer, and that the Marketing Authorization Holder cannot finish the product-specific marketing approval until the Korean manufacturing site holds that accreditation.

Third, a customs-facing document has to be ready before the shipment moves. Japan Customs will only complete clearance of a business-purpose quasi-drug shipment if the importer can show either a valid Manufacturing and Sales Business License, or an Import Confirmation Certificate (輸入確認証) — the document that replaced the older "yakkan shoumei" — obtained in advance from the relevant Regional Bureau of Health and Welfare.

What Happens at Japanese Customs Without These Documents

Japan Customs states plainly that importing quasi-drugs, cosmetics, or medical equipment "for the purpose of business activities" is only permitted for holders of an MHLW-issued business license for importation and sale of those goods. The personal-use import allowance available to individual travelers does not extend to shipments intended for resale.

That distinction matters because Japan Customs also caps personal import of hair-growth agents at a dosage of less than two months, confirming that the product sits in the quasi-drug bucket rather than the cosmetics bucket. Exporters sometimes assume a small first shipment can move under that personal-use allowance. It cannot, once the shipment is declared for business or sales purposes — clearance still depends on the Manufacturing and Sales Business License or Import Confirmation Certificate described above.

The Personal-Use Cap Will Not Clear a Commercial Shipment

A 'trial' shipment is still a commercial shipment

Japan Customs caps personal-use import of hair-growth agents at less than two months' dosage, but that allowance is for individual travelers, not resale. Any shipment imported for business or sales purposes requires an MHLW-issued business license -- the personal-use limit does not apply, no matter how small the shipment is (Japan Customs).

How Much Longer Should You Budget? Quasi-Drug Approval vs. a Cosmetics Notification

An ordinary cosmetics notification in Japan carries no pre-market review at all, according to REACH24H Consulting Group. A quasi-drug application is a different process entirely, and sources describe it with somewhat different numbers: REACH24H cites roughly 9 to 12 months for a typical application, longer if a new active ingredient is involved, while Japan-based quasi-drug contract manufacturer OEM Co., Ltd. cites 6 to 8 months and a cost of up to JPY 1,000,000 for developing and approving a new formulation. Neither figure is an official government-published standard, so the safest planning assumption is a range of roughly six months to a year, on top of the separate Marketing Authorization Holder and Accreditation of the Foreign Manufacturer steps described above.

Pre-Shipment Checklist: What to Confirm Before the First Container Ships

Before committing to a ship date, confirm the active ingredient is on MHLW's approved quasi-drug list at the required concentration, since that decides whether the anti-hair-loss claim can be made at all. Line up a Japan-based Marketing Authorization Holder holding the correct quasi-drug permit, and separately confirm the Korean factory's Accreditation of the Foreign Manufacturer status with PMDA — these are two different approvals held by two different parties. Finally, confirm in advance which document the shipment will present at customs: the Manufacturing and Sales Business License or an Import Confirmation Certificate from the Regional Bureau of Health and Welfare. Building this checklist into the launch timeline, rather than after a shipment is already booked, is what separates a clean market entry from a shipment held at the port.

Pre-Shipment Checklist

• ✓ Confirm the active ingredient is on MHLW's approved quasi-drug list, at the mandated concentrationRequired before an anti-hair-loss claim can legally be made (JPRO)
• ✓ Appoint a Japan-based Marketing Authorization HolderMust hold a 医薬部外品製造販売業許可, distinct from the cosmetics permit (Saitama Prefecture)
• ✓ Obtain Accreditation of the Foreign Manufacturer for the Korean production sitePMDA requires this before the Marketing Authorization Holder can complete product-specific marketing approval
• ✓ Complete product-specific marketing approval for the formulationBudget roughly 6 to 12 months, depending on the source and the active ingredient (REACH24H Consulting Group; OEM Co., Ltd.)
• ✓ Confirm which customs document the shipment will present at clearanceEither the Manufacturing and Sales Business License or an Import Confirmation Certificate from the Regional Bureau of Health and Welfare (Japan Customs)

Last updated: 2026-07. Japan's quasi-drug and cosmetics rules can change, and the regulatory classification of a specific formulation should be confirmed directly with MHLW, PMDA, or a licensed Japanese regulatory consultant before any commercial shipment is booked.

Regulatory Information Disclaimer
This article is provided for informational and reference purposes only. Japan's quasi-drug classification rules, Marketing Authorization Holder requirements, PMDA foreign-manufacturer accreditation procedures, and customs clearance requirements referenced herein are subject to change without notice. Readers should confirm current requirements with MHLW, PMDA, or a licensed Japanese regulatory consultant before finalizing a registration budget or shipment timeline. Korea Industry Insights accepts no liability for actions taken solely on the basis of information in this article.

Frequently Asked Questions

Our shampoo is already registered as a cosmetic back home. Can we just translate the label into Japanese and ship it to our distributor?

No. Japan's classification depends on the claim and the active ingredient, not the label's language or the product's status in another market. Because the product makes an anti-hair-loss claim, it falls into Japan's quasi-drug category alongside deodorants, hair dyes, and medicated whitening or acne products, according to REACH24H Consulting Group. Translating the label does not change that classification or the licensing it requires.

If our shampoo doesn't use one of Japan's MHLW-approved active ingredients, can we still market it as a hair-growth product?

No. A product can only carry a quasi-drug-level claim such as hair-loss prevention if it is formulated with an active ingredient the Ministry of Health, Labour and Welfare has approved for that purpose, at the concentration it specifies, per JPRO's guidance. Without that ingredient, the anti-hair-loss claim has to come off the label, and the product is filed as an ordinary cosmetic instead.

Does our Japanese distributor need to hold the quasi-drug license, or can our Korean factory hold an equivalent license directly?

Both sides need something, and the two are not interchangeable. A Japan-based Marketing Authorization Holder must hold the Quasi-Drug Manufacturing and Sales Business Permit, confirmed by Saitama Prefecture's Pharmaceutical Affairs Division as distinct from the cosmetics permit. Separately, PMDA requires the overseas factory — the Korean production site — to hold its own Accreditation of the Foreign Manufacturer before the Marketing Authorization Holder can complete the product-specific marketing approval.

How much longer should we budget for quasi-drug approval, and can we sell in Japan as an ordinary cosmetic while it's pending?

Budget meaningfully more time than a cosmetics filing needs. Sources describe a range: REACH24H Consulting Group cites roughly 9 to 12 months for a typical application, longer with a new active ingredient, while OEM Co., Ltd. cites 6 to 8 months and up to JPY 1,000,000 for a new formulation, against no pre-market review at all for an ordinary cosmetics notification. Selling in Japan as a plain cosmetic in the meantime is only possible if the anti-hair-loss claim is dropped entirely, since that claim is not legally permitted outside the quasi-drug track.

Is there a faster, one-time path, like an import confirmation certificate, that lets a trial shipment clear customs before we finish the full license and approval process?

Japan Customs will clear a business-purpose quasi-drug shipment if the importer presents either a valid Manufacturing and Sales Business License or an Import Confirmation Certificate (輸入確認証, the document that replaced the former yakkan shoumei), obtained in advance from the relevant Regional Bureau of Health and Welfare. The certificate is a documented alternative to holding the full manufacturing and sales license, but it still has to be secured before the shipment arrives — it is not something customs issues on the spot.

More from Korea Industry Insights

• China NMPA Special Cosmetics Registration: What Anti-Hair-Loss Shampoo Importers Must Know
• Mexico Women's Apparel Market Opportunity: Why a 35% Tariff Changes the Entry Strategy